A Randomized, Controlled Trial Comparing the Immunogenicity of 2 Doses Versus 3 Doses of the 9-Valent HPV Vaccine in Males and Females 15 to 26 Years of Age
We will conduct a clinical trial to examine the immune response of older teens and young adults who receive 3 doses of the HPV vaccine as compared to the immune response of those who receive only 2 doses. We hypothesize that the immune responses will be similar, demonstrating that 2 doses are adequate in those 15 years of age and older. Simplifying the HPV vaccine schedule for older teens and young adults would likely increase the number of individuals who complete the series.
Academic Research; vaccine research
Males; Females; 15 to 26 Years of Age
Cervix Uteri; Head and Neck; Penis; HPV-related
The University of Texas Medical Branch at Galveston